Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9UIF7
UPID:
MUTYH_HUMAN
Alternative names:
MutY homolog
Alternative UPACC:
Q9UIF7; D3DPZ4; Q15830; Q9UBP2; Q9UBS7; Q9UIF4; Q9UIF5; Q9UIF6
Background:
Adenine DNA glycosylase, also known as MutY homolog, plays a crucial role in oxidative DNA damage repair. It initiates the repair of A*oxoG to C*G by removing the inappropriately paired adenine base, showcasing adenine and 2-OH-A DNA glycosylase activities.
Therapeutic significance:
Linked to diseases like Familial adenomatous polyposis 2 and Gastric cancer, understanding the role of Adenine DNA glycosylase could pave the way for novel therapeutic strategies targeting these conditions.